Abstract
AbstractExtracellular vesicle (EV)-based therapy was hypothesized as a promising regenerative approach which has led to intensive research of EVs in various pathologies. In this study, we performed a comprehensive systematic review of the current experimental evidence regarding the protective properties of EVs in chronic kidney disease (CKD). We evaluated the EV-based experiments, EV characteristics, and effector molecules with their involvement in CKD pathways. Including all animal records with available creatinine or urea data, we performed a stratified univariable meta-analysis to assess the determinants of EV-based therapy effectiveness. We identified 35 interventional studies that assessed nephroprotective role of EVs and catalogued them according to their involvement in CKD mechanism. Systematic assessment of these studies suggested that EVs had consistently improved glomerulosclerosis, interstitial fibrosis, and cell damage, among different CKD models. Moreover, EV-based therapy reduced the progression of renal decline in CKD. The stratified analyses showed that the disease model, administered dose, and time of therapeutic intervention were potential predictors of therapeutic efficacy. Together, EV therapy is a promising approach for CKD progression in experimental studies. Further standardisation of EV-methods, continuous improvement of the study quality, and better understanding of the determinants of EV effectiveness will facilitate preclinical research, and may help development of clinical trials in people with CKD.
Graphical Abstract
Funder
Uniwersytet Medyczny w Bialymstoku
Publisher
Springer Science and Business Media LLC
Reference71 articles.
1. GBD Chronic Kidney Disease Collaboration. (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 [published online February 13, 2020]. Lancet. Cockwell P and Fisher L. The global burden of chronic kidney disease [published online February 13, 2020]. https://doi.org/10.1016/S0140-6736(19)32977-0
2. Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020). Targeting the progression of chronic kidney disease. Nature Reviews Nephrology, 16(5), 269–288.
3. Breyer, M. D., & Susztak, K. (2016). Developing Treatments for Chronic Kidney Disease in the 21st Century. Seminars in Nephrology, 36(6), 436–447.
4. Ix, J. H., & Shlipak, M. G. (2018). Trial of pirfenidone to prevent progression of chronic kidney disease. (available online at http://grantome.com/grant/NIH/U01-DK111510-01A1)
5. van der Pol, E., Böing, A. N., Gool, E. L., & Nieuwland, R. (2016). Recent developments in the nomenclature, presence, isolatin, detection and clinical impact of extracellular vesicles. Journal of Thrombosis and Haemostasis, 14(1), 48–56.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献